Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of TAK-935 add-on therapy in pediatric developmental and/or epileptic encephalopathy
MOH_2019-01-20_004922Phase 2Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dravet syndrome and Lennox-Gastaut syndrome (LGS) comparing Standard therapy + placebo with Standard therapy + TAK-935 (2 arms). Planned start Nov 2018; status: not yet recruiting.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on MOH_2019-01-20_004922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-20_004922.